Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

Fernández-Ortega, Paz; Caloto, M.T.; Chirveches, E.; Marquilles, R.; Francisco, J. San; Quesada, Ana R.; Suárez, Cristina; Zorrilla, Iñaki; Gómez, Jesús García; Zabaleta, P.; Nocea, G; Llombart-Cussac, Antonio

doi:10.1007/s00520-012-1448-1

Cited by 150 publications

(114 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those authors observed that 40% to 45% of patients experienced CINV that significantly affected their quality of life, as estimated by a functional living index-emesis questionnaire, and that those who experienced significant nausea did so in 90% of chemotherapy cycles. 11 In another study of quality of life in a community hospital-based setting, approximately 33% of patients reported that CINV had a substantial impact on their daily lives. Both acute and delayed CINV affected quality of life, but only the presence of acute CINV influenced antiemetic treatment, suggesting that delayed effects are not being appropriately addressed.…”

Section: Discussionmentioning

confidence: 99%

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Gomez

Liao

Giordano

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND: Nausea and vomiting (N/V) during chemotherapy can have profound clinical and economic consequences. Effective antiemetic agents are available for prophylaxis, but barriers may prevent their use. For this population-based study, the authors assessed the rates of antiemetic prophylaxis use, and predictors of such use, among patients who were receiving platinum-based chemotherapy for lung cancer between 2001 and 2007. METHODS: The authors searched the Texas Cancer Registry-Medicare-linked database for individuals aged >65 years who received platinum-based chemotherapy within 12 months after a first diagnosis of lung cancer from 2001 to 2007; and all patients had continuous Medicare Part A and Part B coverage for the same period. Adherence to recommended regimens for N/V prophylaxis (established by the National Comprehensive Cancer Network) was scored as a binary variable (adherent vs nonadherent) and was calculated as the percentages of treated patients receiving each recommended agent within 1 day of beginning chemotherapy. Logistic regression with stepwise selection was used to examine whether patient characteristics influenced adherence. RESULTS: Of 4566 selected patients, adherence rates for the receipt of serotonin antagonists (eg, ondansetron) with dexamethasone were 60% to 90% regardless of whether the chemotherapy agent was considered moderately or highly emetogenic. The receipt of substance-P antagonists was much less common (<10%) during any period. On multivariate logistic regression modeling, variables that predicted adherence were older age, white race, higher median income, and concurrent radiation therapy. CONCLUSIONS: Recommended use of antiemetics for prophylaxis, especially substance-P antagonists, during chemotherapy for lung cancer is suboptimal. Factors that were correlated with adherence suggest socioeconomic barriers in the community. Cancer INTRODUCTIONNausea and vomiting during chemotherapy can have profound clinical and economic consequences, including malaise, dehydration, electrolyte abnormalities, weight loss, feeding tube placement, hospitalization, and death. These symptoms also can lead to decreased treatment adherence and, hence, inadequate therapy. In 1 population-based analysis, Burke et al studied the clinical impact of chemotherapy-induced nausea and vomiting (CINV) from agents considered at high or moderate risk of inducing emesis and observed that, after the first cycle of chemotherapy, the risk of resultant inpatient admissions, emergency room visits, or outpatient hospital visits was 18%. Those authors also observed that the cost of treating patients who experienced CINV after the first cycle could reach $9578 per patient. They concluded that visits for CINV during the first cycle of chemotherapy were both common and costly and that strategies to reduce the incidence of CINV could reduce health care use and cost.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Gomez

Liao

Giordano

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“…This adverse event impairs patients' quality of life and exerts a negative influence on patient's desire to continue the chemotherapy (1,2).…”

mentioning

confidence: 99%

Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer

Nawa-Nishigaki

Kobayashi

Suzuki

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There are two symptoms that appear quite frequently so at this stage: the general feeling of wear without apparent cause and difficulties with memory. 8,9,13,[17][18][19][20] In this study 75,0% of patients were at this stage.…”

Section: Stress In Patients …mentioning

confidence: 85%

“…4,16,20 The nature of the symptoms, the majority of patients with stress had a greater amount of physical symptoms, followed by psychological symptoms. The prevailing stress resistance of the layer was followed by phase near exhaustion.…”

Section: Stress In Patients …mentioning

confidence: 99%

Estresse em pacientes submetidos a tratamento antineoplásico Stress in patients submitted to drug therapy

Oliveira

Rodrigues

Ferreira

et al. 2016

R. pesq. cuid. fundam. online

View full text Add to dashboard Cite

Objetivo: Avaliar o nível de estresse de pacientes que estavam recebendo tratamento antineoplásico, quais os estressores referentes a essa situação e examinar a relação do mesmo com variáveis sociodemográficas e da doença oncológica. Método: Estudo descritivo, exploratório, com abordagem quantitativa, realizado em um ambulatório de onco-hematologia de um hospital privado, de grande porte, localizado no município de São Paulo. Utilizou-se um formulário que continha informação sociodemográfica e instrumento para a avaliação do estresse (Inventário de Sintomas de Estresse de Lipp). Resultados: a maior parte dos participantes do sexo feminino (56,0%), com idade entre 41 a 50 anos (34,0%), apresentava câncer gastrointestinal (31,0%), 78,0% dos pacientes apresentaram estresse, sendo a náusea e a alopecia os efeitos colaterais mais citado pelos entrevistados, ambos com 16,0%, tornando-se os maiores estressores no tratamento. Conclusão: Uma proporção importante de pacientes sofria de estresse. Destarte, torna-se essencial o acompanhamento da enfermagem a esses pacientes que conduza a enfrentar melhor a neoplasia.

show abstract

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life

Cited by 150 publications

References 29 publications

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer

Estresse em pacientes submetidos a tratamento antineoplásico Stress in patients submitted to drug therapy

Contact Info

Product

Resources

About